[3] Guan Z Z， Xu J M， Luo R C， et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer： a randomized phase Ⅲ ARTIST trial[J]. Chin J Cancer， 2011， 30（10）： 682-689.
[4] Giantonio B J， Catalano P J， Meropol N J， et al. Bevacizumab in combination with oxaliplatin， fluorouracil， and leucovorin （FOLFOX4） for previously treated metastatic colorectal cancer： results from the Eastern Cooperative Oncology Group Study E3200[J]. J Clin Oncol， 2007， 25（12）： 1539-1544.
[5] Van Cutsem E，Rivera F，Berry S，et al. Safety and efficacy of first line bevacizumab with FOLFOX，XELOX，FOLFIRI and fluoropyrimidines in metastatic colorectal cancer： the BEAT study [J]. Ann Oncol，2009，20（11）： 1842-1847.
[6] Raez L E， Santos E S， Webb R T， et al. A multicenter phaseⅢ study of docetaxel， oxaliplatin， and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer （NSCLC）[J]. Cancer Chemother Pharmacol， 2013， 72（5）： 1103-1110.
[7] Burger R A， Brady M F， Rhee J， et al. Independent radiologic review of the gynecologic oncology group study 0218， a phaseⅢ trial of bevacizumab in the primary treatment of advanced epithelial ovarian， primary peritoneal， or fallopian tube cancer[J]. Gynecol Oncol， 2013， 131（1）： 21-26.
[8] Schefter T， Winter K， Kwon J S，et al. RTOG 0417： Efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma[J]. Int J Radiat Oncol Biol Phys， 2014， 88（1）：101-105.
[9] Sohal D P， Metz J M， Sun W， et al. Toxicity study of gemcitabine， oxaliplatin， and bevacizumab， followed by 5-fluorouracil， oxaliplatin， bevacizumab， and radiotherapy， in patients with locally advanced pancreatic cancer[J]. Cancer Chemother Pharmacol， 2013， 71（6）： 1485-1491.
[10] Uronis H E， Bendell J C， Altomare I， et al. A phaseⅡ study of capecitabine， oxaliplatin， and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas[J]. Oncologist， 2013， 18（3）： 271-272.
[11] Balar A V， Apolo A B， Ostrovnaya I， et al. PhaseⅡ study ofgemcitabine， carboplatin， and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer[J]. J Clin Oncol， 2013， 31（6）： 724-730.
[12]朱春荣，熊峰，朱彦博，等.贝伐单抗联合FOLFOX4或FOLFIRI方案治疗晚期结直肠癌的临床观察[J].江苏医药，2012，38（19）：2306-2307.
[13] Gressett S M， Shah S R. Intricacies of bevacizumab-induced toxicities and their management[J]. Ann Pharmacother， 2009， 43（3）： 490-501.
